 |
|
|
| |
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis
|
| |
| |
EASL 2023 June 23 Vienna
Christiana Graf1,2, Roberta D'Ambrosio3, Elisabetta Degasperi3, Stefania Paolucci4, Jordi Llaneras5, Johannes Vermehren1, Georg Dultz1, Kai-Henrik Peiffer1, Eva Herrmann6, Stefan Zeuzem1,7, Maria Buti5, Pietro Lampertico3,8, Julia Dietz1,7 Christoph Sarrazin1,7,9
"we retreat SOF/Vel/Vox failures with G/P+SOF, and 2 patients in the study who were decompensated with Child Pugh cirrhosis they were retreated with G/P+Sof." Graf
|
| |
|
|
|
|
|
